Precision Therapeutics (NASDAQ:POAI) and Wound Management Technologies (OTCMKTS:WNDM) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.
Earnings & Valuation
This table compares Precision Therapeutics and Wound Management Technologies’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Precision Therapeutics||$1.41 million||12.84||-$10.09 million||N/A||N/A|
|Wound Management Technologies||$5.84 million||1.83||-$600,000.00||N/A||N/A|
Wound Management Technologies has higher revenue and earnings than Precision Therapeutics.
Volatility & Risk
Precision Therapeutics has a beta of 2.42, meaning that its stock price is 142% more volatile than the S&P 500. Comparatively, Wound Management Technologies has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.
This is a breakdown of current ratings and target prices for Precision Therapeutics and Wound Management Technologies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Wound Management Technologies||0||0||0||0||N/A|
This table compares Precision Therapeutics and Wound Management Technologies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Wound Management Technologies||-10.28%||-39.28%||-21.49%|
Institutional & Insider Ownership
1.1% of Precision Therapeutics shares are owned by institutional investors. 13.4% of Precision Therapeutics shares are owned by insiders. Comparatively, 75.4% of Wound Management Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Wound Management Technologies beats Precision Therapeutics on 6 of the 9 factors compared between the two stocks.
About Precision Therapeutics
Predictive Oncology Inc. provides various healthcare products and services primarily in the United States. The company manufactures environmentally conscious systems for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care. It offers the STREAMWAY Fluid Waste Management system that suctions surgical waste fluid from the patient using standard surgical tubing; and disposables. The company also provides contract research organization (CRO) that offers personalized medicine solutions for pharmaceutical, diagnostic, and biotech industries. Its CRO services enhance the effectiveness of cancer therapy using the power of artificial intelligence applied to diseases databases. The company markets and sells its STREAMWAY Fluid Waste Management system and procedure disposables to medical facilities through various direct sales force and independent distributors. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was founded in 2002 and is based in Eagan, Minnesota.
About Wound Management Technologies
WNDM Medical Inc. develops, markets, and distributes biotechnology products to physicians, hospitals, and clinics in the United States. The company offers HemaQuell, a resorbable bone hemostat for bone healing; and CellerateRX surgical for healing. The company was formerly known as Wound Management Technologies, Inc. and changed its name to WNDM Medical Inc. in April 2017. WNDM Medical Inc. was founded in 1982 and is based in Fort Worth, Texas.
Receive News & Ratings for Precision Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.